Expanded access to CAR T-cell therapies in Ireland for adults with certain blood cancers

Gilead Sciences Ltd. and Kite, a Gilead company, have announced that two CAR T-cell therapies have been reimbursed through the public health system in Ireland for the treatment of eligible adult patients with certain blood cancers.

Yescarta® (axicabtagene ciloleucel; axi-cel) is now reimbursed in Ireland as an option for eligible adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months of completion of, or is refractory to, first-line treatment.